SB 293 requires nursing homes, assisted living facilities, and nurse midwives to notify residents and prospective residents in writing if they lack professional liability insurance or if coverage has lapsed without renewal. For prospective residents, notification must occur at the first visit during a coverage gap or at the time of application; current residents must be notified within 30 days of a lapse. Facilities without coverage must also post a conspicuous notice visible to residents and guests. This law aims to increase transparency about insurance coverage for individuals receiving care in these settings.
SB 444 repeals an exemption that previously allowed intermediate care facilities offering substance use disorder treatment to change bed capacity without a certificate of need. It creates a new exemption for facilities providing *medically managed residential substance use disorder treatment services*, removing the requirement for a certificate of need if they submit 45 days' written notice to the Commission and the Commission determines the change aligns with the state health plan, improves service efficiency, and serves the public interest. This bill directly affects intermediate care facilities focused on substance use disorder treatment by reducing regulatory barriers for expanding bed capacity or establishing new facilities. The key mechanism is replacing a certificate of need with a streamlined notice-and-review process administered by the Commission. (SB 444, "Certificate of Need - Intermediate Health Care Facilities," 2026)
HB 498 removes an existing exemption that allowed intermediate care facilities providing substance use disorder treatment to change bed capacity without a certificate of need. It specifically targets facilities offering "medically managed residential substance use disorder treatment services," requiring them to file 45 days' written notice with the health commission before operating or expanding. The commission must then review and approve these changes based on whether they align with the state health plan, improve service efficiency, and serve the public interest. This bill directly affects facilities providing residential substance use treatment by adding a review process for bed capacity changes or new operations, replacing the previous exemption.
HB 1445, the "Maryland Protecting People With Disabilities Act," changes eligibility rules for home- and community-based services under Maryland's Medicaid program (Maryland Medical Assistance Program). It requires the state to continue services uninterrupted during appeals if an individual loses eligibility, prohibits automatic termination solely due to administrative errors (procedural disenrollment), and mandates data sharing between providers and the Department of Health. The bill directly affects people receiving Developmental Disabilities Administration services and Medicaid beneficiaries who risk losing community-based care due to eligibility disputes. Key provisions include extending appeal timelines (replacing 90-day deadlines with continuous service until appeal resolution) and requiring the state to reserve waiver slots for those who lost eligibility unfairly. These changes aim to align with the Olmstead v. L.C. Supreme Court ruling protecting community integration rights.
HB 1117 requires Maryland's Medicaid program (Maryland Medical Assistance Program) and certain insurers to cover approved "elopement response devices" for specific individuals. These devices - such as door sensors, wearable location trackers, or alert systems - prevent people with cognitive, developmental, or neurological conditions from wandering unsafely (e.g., leaving a supervised area without the ability to return safely). Coverage is mandated when ordered by a qualified healthcare provider and documented in a qualifying plan (like an individualized education plan or dementia care plan) for eligible recipients: those under 21 with early screening eligibility, on home-based waiver programs, or diagnosed with Alzheimer’s/dementia. The bill defines these devices as medical equipment or assistive technology under state programs, ensuring coverage without regard to when the program was established.
HB 797 prohibits employers from discriminating against fire and rescue public safety employees who use medical cannabis, provided they have a valid written certification from a licensed healthcare provider under Maryland's medical cannabis program. The bill modifies existing law to clarify that an employer cannot take adverse employment actions (like termination or denial of promotion) solely due to medical cannabis use, as long as the employee meets the state's certification requirements. It updates definitions in Maryland law to ensure fire and rescue employees qualify for the same protections as other medical cannabis patients under the existing program. The law does not override workplace safety rules or require employers to accommodate cannabis use during work hours.
This bill requires Maryland counties with volunteer fire companies to provide no-cost preventive cancer screenings to volunteer firefighters, as defined by the bill. Volunteer fire companies must maintain and annually submit a list of their volunteer firefighters to the county, which must then keep this list on file. Counties can meet this requirement by either offering a free annual health exam including cancer screenings or applying for a specific grant to fund advanced screening technologies like multi-cancer blood tests. The law applies to all counties with volunteer fire companies and takes effect July 1, 2026.
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
HB 417 (Public Health - Medetomidine and Xylazine Consumer Protection Act) regulates the sale of veterinary drugs medetomidine and xylazine. It prohibits retailers from selling these products without proof the buyer intends to use them for veterinary, scientific, or institutional purposes, and bans sales to anyone under 21. Retailers must maintain records of sales, including age verification and proof of intended use. Violations carry civil fines up to $6,500 per offense, with penalties deposited into Maryland's Substance Abuse Fund. The bill directly affects pharmacies, veterinary suppliers, and online retailers selling these specific products.
HB 1167 requires Maryland's Department of Health to replace its outdated Medicaid computer system with a modern, flexible system by 2028. The new system must maintain all current Medicaid functions - including processing medical/dental/pharmacy claims, provider enrollment, and beneficiary inquiries - while meeting federal security and performance standards. The bill mandates integration with existing Medicaid systems by January 2027 and full replacement of the old system by January 2028, subject to federal approval. This change directly affects Medicaid beneficiaries and healthcare providers through more reliable service delivery.
